United States Specialty Pharmacy Market Size, Share, Growth and Forecast, 2025-2035

United States specialty pharmacy value rests on few networks

The United States specialty pharmacy market was valued at USD 292.99 billion in 2025 and is projected to increase from USD 318.00 billion in 2026 to USD 625.11 billion by 2035, registering a CAGR of 7.80% during 2026–2035. Demand comes from oral oncology drugs, self-injected immunology biologics and a growing list of orphan medicines that need cold-chain handling, payer authorization and nurse support. South held the largest regional share, 37.5% in 2025, and also grows fastest at 8.08% a year as Census Bureau counts show the region adding the most residents. Commercial plans still pay for half of dispensed value, while the $2,100 Medicare Part D out-of-pocket cap that took effect in 2026 keeps more older patients on expensive therapy. Medicare negotiated prices on 15 more drugs begin in 2027, which shifts pharmacy economics toward clinical services and away from a percentage of list price.

What does the specialty dispensing market count and leave out?

The market counts prescription revenue from specialty drugs dispensed by central-fill, health-system, independent and retail-affiliated pharmacies to patients at home or at a clinic. Value is measured at the pharmacy level, so it captures the drug cost plus the dispensing, care-management and patient-access work bundled with each fill.

The estimate excludes provider-administered drugs billed under the medical benefit, which physician offices and hospital outpatient departments buy and bill themselves. It also excludes standard retail prescriptions, manufacturer hub fees paid outside the dispensing claim and infusion nursing billed separately from the drug.

Immunology and PBM networks anchor dispensing value

Why does immunology carry the largest therapy share?

Based on therapy area, the market is categorized into immunology, oncology, neurology and rare and genetic diseases. Immunology led with 38.0% of 2025 value because self-injected anti-inflammatory biologics sit under the pharmacy benefit, and Tremfya added subcutaneous approvals for Crohn's disease in March 2025 and ulcerative colitis in September 2025. Oncology follows on oral agents such as Ibrance and Xtandi. Rare and Genetic Diseases grows fastest at 9.28% a year as approvals reach conditions with few options, including Qfitlia for hemophilia on March 28, 2025, and Ekterly for hereditary angioedema on July 3, 2025, according to the FDA.

How does the modality mix shift toward complex products?

Based on drug modality, the market is categorized into small-molecule specialty drugs, biologics, biosimilars and cell and gene therapies. Biologics led with 58.0% of 2025 value because payers route high-cost injectables through managed dispensing networks, and the FDA cleared 12 novel biologics in 2025 alone. Biosimilars gained 18 further FDA approvals that year, which adds lower-cost options to the same channel. Cell and Gene Therapies grows fastest at 13.77% a year from a very small base as the CMS access model for sickle cell gene therapies, announced July 15, 2025, brings 33 states into outcomes-based payment.

Who controls the prescriptions and who is gaining ground?

Based on distribution channel, the market is categorized into PBM-affiliated central fill, health-system, independent and retail-affiliated specialty pharmacy. PBM-Affiliated Central Fill led with 68.0% of 2025 value because the three largest dispensers, all tied to PBMs, took about two-thirds of prescription revenue, according to Becker's Hospital Review in April 2026. Retail-affiliated players such as Walgreens and Walmart count store fills as well. Health-System Specialty Pharmacy grows fastest at 9.77% a year as hospital programs reached 28% of accredited sites in 2025, which places dispensing next to the prescribing clinic and its medical records.

Which payers fund dispensing and which group grows fastest?

Based on customer type, the market is categorized into commercially insured members, Medicare beneficiaries, Medicaid beneficiaries and cash-pay and assistance patients. Commercially Insured Members led with 50.0% of 2025 value because employers covered 53.8% of Americans in 2024, according to Census Bureau data reported by Fierce Healthcare. Medicaid remains price-constrained, with KFF showing rebates cutting gross drug spending by 53% on average from fiscal 2019 to fiscal 2024. Medicare Beneficiaries grows fastest at 8.41% a year as the program covered 19.1% of Americans in 2024 and the 2026 Part D cap limits what older patients pay at the counter.

Orphan approvals and the Part D cap widen treated demand

Expanding specialty-therapy pipeline adds new fills

New approvals remain the most direct source of added dispensing value because most launches now target small, complex patient groups. The FDA drug center approved 46 novel drugs in 2025, and 23 of them carried orphan status while 20 were first in class. Several are dispensed for home use, including Palsonify for acromegaly on Sept. 25, 2025, and Jascayd for idiopathic pulmonary fibrosis on Oct. 7, 2025. Cancer launches in capsule and tablet form followed, with Komzifti on Nov. 13, 2025, and Hyrnuo on Nov. 19, 2025, which added self-administered oncology fills rather than clinic infusions. As a result, Rare and Genetic Diseases expands at 9.28% a year, the quickest pace among therapy groups in the Credence Research model.

Coverage expansion and affordability reform aid persistence

Federal reform matters because abandonment falls when patients can predict what a costly fill will cost them. The Medicare Part D out-of-pocket cap stands at $2,100 for 2026, according to Pharmaceutical Commerce in February 2026, and the first ten negotiated prices took effect on Jan. 1, 2026. In parallel, the CMS Cell and Gene Therapy Access Model covers about 84% of Medicaid beneficiaries with sickle cell disease across 33 states, the District of Columbia and Puerto Rico, according to a CMS release of July 15, 2025. Those states can also draw up to $9.55 million each in federal support. Together these steps underpin the 8.41% annual growth modeled for Medicare Beneficiaries.

Download Free Sample

High chronic-disease burden sustains long-duration therapy

Disease prevalence sets the floor under dispensing volume because most specialty regimens run for years rather than weeks. The American Cancer Society projects about 2,114,850 new cancer cases and 626,140 cancer deaths in the country during 2026, which keeps oral oncolytic demand large and steady. The National Organization for Rare Disorders counted more than 30 million Americans living with a rare disease in February 2026, or about one in ten residents. Among older adults, about 5.3 million Part D enrollees took one of the 15 drugs chosen for 2027 negotiation during 2024, according to CMS. Those long regimens help explain why Immunology alone held 38.0% of 2025 value.

Subcutaneous launches move therapy into the pharmacy benefit

A newer driver is the shift of intravenous brands into injections that patients or nurses can give outside the hospital, which also complements home infusion therapy programs. Managed Healthcare Executive reported in December 2025 that intravenous drugs usually fall under the medical benefit while subcutaneous versions fall under the pharmacy benefit. Leqembi Iqlik launched in October 2025 at $375 per autoinjector, or $19,500 a year, against a $26,632 annual list price for the infused form. The FDA approved Keytruda Qlex on Sept. 19, 2025, following Opdivo Qvantig in December 2024, although these remain clinician-given and mainly shorten chair time. Leqembi Iqlik is therefore the clearer case of a brand entering pharmacy channels.

Health systems and private-label biosimilars reset access

Rise of hospital-owned dispensing programs

Hospitals are pulling specialty prescriptions back toward the clinic that writes them, which is the clearest channel shift of this decade. Becker's Hospital Review reported on April 21, 2026 that accredited hospital and health-system locations rose from 106 in 2017 to 553 in 2025. The national count passed 1,900 accredited sites, up 3% in a year and more than five times the 2015 figure. Payers are moving the same way, as Elevance Health closed its purchase of Paragon Healthcare on March 11, 2024, adding more than 40 ambulatory infusion centers in eight states. As a result, Health-System Specialty Pharmacy grows at 9.77% a year while central-fill share slowly declines.

Shift toward private-label biosimilar programs

PBM-linked private labels are turning biosimilars from a slow substitution story into a formulary decision made in a single plan year. Samsung Bioepis reported in its second-quarter 2026 review that 92 biosimilar medicines had won approval in the country across 20 molecules by March 2026, with 67 already launched. Adalimumab biosimilars reached 60% share in February 2026, a jump the same review partly attributes to counting Quallent private-label sales. Ustekinumab versions held 27% by the fourth quarter of 2025, which shows the next immunology conversion is already underway. In turn, Cell and Gene Therapies and biosimilar products both outgrow Biologics through 2035.

Download Free Sample

Opening in cell and gene therapy coordination

Cell and gene therapies create an opening for pharmacies that can coordinate logistics, payer contracts and long follow-up rather than simply ship a product. Combined approvals from the two FDA review centers reached 58 in 2025, which widened the list of complex products needing coordination. The agency also removed REMS programs for six autologous CAR-T therapies, according to Regulatory Focus on June 30, 2025, and cut the required stay near a treatment facility from four weeks to two. Sites outside large academic centers can therefore treat more patients, while manufacturers still owe 15 years of postmarketing follow-up. Pharmacies with outcomes-tracking capability are well placed because CMS ties its sickle cell model to rebates if a therapy fails, and that tracking work has real value.

Opening in rare-disease limited distribution

Rare disease offers the widest unmet need, which favors dispensers that manufacturers trust with small, closely tracked patient groups. The National Organization for Rare Disorders counts more than 10,000 known rare diseases, and fewer than 5% have an approved treatment. New products keep arriving for these patients, including Gomekli on Feb. 11, 2025, Forzinity on Sept. 19, 2025, and Kygevvi on Nov. 3, 2025, according to the FDA. PANTHERx Rare Pharmacy ranked sixth by dispensing revenue among all dispensers on the 2025 list published by Becker's, which shows that a focused independent can reach national scale. Independents with disease-specific nurses can win these launches because contract terms reward data capture.

Negotiated prices and coverage losses squeeze margins

How much will Medicare negotiation take from specialty revenue?

Negotiated prices cut the revenue base directly for pharmacies whose income follows list price. CMS set 2027 discounts of 65% for Otezla, 60% for Pomalyst, 50% for Ibrance and 48% for Xtandi, against 2024 list prices, and estimated USD 12 billion in savings across the 15 drugs. Oncology dispensers feel this first because three of those products are cancer drugs. Fee-based contracts and added clinical services offer the most practical offset for affected pharmacies.

Will coverage losses interrupt therapy for lower-income patients?

Coverage is eroding, which threatens persistence among working-age patients on expensive regimens. AJMC reported on Oct. 22, 2026 that the Commonwealth Fund measured uninsurance among adults 19 to 64 at 11.2% in 2026, up from 8.9% in 2024, while KFF showed effectuated marketplace enrollment falling from 22.1 million in 2025 to 19.2 million in February 2026. The Congressional Budget Office projected that the 2025 reconciliation law will add 10 million uninsured people by 2034, according to KFF in August 2025. Pharmacies carry more unpaid work as a result, so assistance-program staffing becomes a real cost.

What does PBM regulation mean for affiliated dispensers?

Vertical integration faces direct legal attack, which clouds long-range planning for the largest networks. The FTC said in January 2025 that the three largest benefit managers marked up dozens of specialty generics by hundreds and thousands of percent. Arkansas Act 624 banned PBM ownership of pharmacies, although a federal judge blocked it on July 28, 2025, and Tennessee passed a similar ban in May 2026. Federal delinking for Part D then starts in 2028, according to HLTH.

How could the 340B rebate pilot affect hospital programs?

Hospital programs depend on 340B margins, so a move from upfront discounts to rebates can strain their cash flow. A federal court blocked the first HRSA pilot on Dec. 29, 2025, and HRSA then revived it with a Jan. 1, 2027 start, according to Baker Donelson in August 2026. The pilot covers only negotiated-drug-list products, under 5.5% of 2025 340B sales volume, which limits the first exposure. Finance teams still need reserves in case the list widens later.

The South holds the largest share of dispensed therapy

South leads on population and adds residents fastest

The South held 37.5% of 2025 value and grows at 8.08% a year, the fastest pace among the four regions. Census Bureau estimates released in January 2026 show 133.8 million residents there in July 2025, a gain of about 1.17 million in one year. Texas reached 31.7 million people and Florida 23.5 million, which supports large oncology and immunology patient pools. Plano, Texas, also hosts Paragon Healthcare, the infusion and drug therapy company Elevance Health acquired in March 2024.

West growth depends on large coastal markets and new rules

The West held 25.0% of 2025 value and grows at 7.83% a year, with 80.1 million residents recorded by the Census Bureau for July 2025. California alone accounts for 39.4 million of them, so its rules carry weight across the region. Governor Gavin Newsom signed SB 41 on Oct. 11, 2025, and AMCP reports that it bans spread pricing in plan contracts from Jan. 1, 2026, and bars steering patients to affiliated pharmacies. Independent and health-system dispensers in the state stand to gain from these limits.

Download Free Sample

Midwest share holds as population gains slow

The Midwest held 19.5% of 2025 value and grows at 7.58% a year, reflecting slower population gains than the South. The Census Bureau counted 69.8 million residents in July 2025, up only about 244,000 from a year earlier, which limits new patient flow across the region. Illinois, with 12.7 million people, has passed the Prescription Drug Affordability Act, which HLTH reports bans steering patients to PBM-owned pharmacies and faces a federal lawsuit from the PBM trade group. Hospital-owned dispensers would benefit most if that law survives its court test.

Northeast grows slowest from a mature, well-served base

The Northeast held 18.0% of 2025 value and grows at 7.38% a year, the slowest pace of the four regions. Census Bureau data show 58.0 million residents in July 2025, a gain of only about 102,000 in a year, while New York stayed flat at 20.0 million people. Slow population growth means value here depends more on therapy mix than on new patients. Credence Research expects dense academic hospital networks in the region to favor hospital-owned dispensing over mail-based central fill.

Download Free Sample

Dated moves reshaping dispensing, access and price

Autoinjectors and traceability change the service model

• Subcutaneous autoinjectors take about 15 seconds in the case of Leqembi Iqlik, against an hour-long infusion, which moves training and adherence calls to the pharmacy.
• Drug supply chain tracing under the Drug Supply Chain Security Act requires trading partners, including dispensers, to exchange transaction data at the package level, and the FDA has exempted pharmacies with 25 or fewer full-time employees from certain requirements until Nov. 27, 2027, according to Pharmaceutical Commerce.
• Outcomes tracking supports the rebates that CMS attaches to sickle cell gene therapies when a treatment fails to deliver its promised benefit.
• Post-treatment monitoring continues for CAR-T patients because manufacturers must still follow them for 15 years under postmarketing study requirements set by the FDA.

Three vertically integrated networks set the terms

Competition centers on network access first and clinical capability second. The 2025 ranking published by Becker's Hospital Review places CVS Specialty first, Accredo second and Optum Specialty Pharmacy third by dispensing revenue, followed by Walgreens Specialty Pharmacy and the combined Onco360 and CareMed business. PANTHERx Rare Pharmacy, CenterWell Specialty Pharmacy, BioPlus with Paragon, AcariaHealth with Foundation Care and Walmart Specialty Pharmacy complete the top ten. The largest three hold their position through plan networks, while oncology and rare-disease specialists compete for manufacturer contracts on data quality and nurse support. Walgreens and Walmart also count fills from their wider retail store networks, which gives them neighborhood reach that central-fill sites lack. Health-system programs compete on a different basis, using shared medical records and fast clinic handoffs to retain patients.

Who ranks where among national dispensers?

Service depth will matter more than dispensing scale

Credence Research's view is that dispensing scale alone will earn less each year through 2035. Negotiated Medicare prices, state limits on spread pricing and federal delinking all reduce the value of a percentage-of-price model. The pharmacies best placed are those that can document clinical outcomes, manage prior authorization and retain patients across long regimens. Hospital-owned programs hold a natural advantage in oncology and transplant, while disease-focused independents can win rare launches. PBM-linked networks will keep most of the value, although their margin mix should move toward fees and away from generic spreads.

How the dispensing value was modeled and checked

The report uses 2025 as the base year and 2035 as the forecast year, with market values taken from the Credence Research model. Regional, segment and customer splits are Credence Research estimates informed by public data and are not reported statistics. Sources include FDA and CMS publications, Census Bureau population estimates, the American Cancer Society, the National Organization for Rare Disorders, KFF, Commonwealth Fund survey coverage and trade press reporting on channel structure. No interviews or surveys were conducted for this edition, so channel shares should be read as modeled ranges.

Volume growth outruns price pressure through 2035

From USD 318.00 billion in 2026, the market is expected to reach USD 625.11 billion by 2035 as treated patient counts rise faster than net price pressure. Therapy mix will keep moving toward rare diseases, and self-injected launches should continue to bring neurology and some oncology brands into pharmacy channels. Medicare negotiation will widen as new drug lists arrive each year, which keeps pressure on oral oncology and immunology revenue. Health-system dispensers should hold a larger share by 2035, although central-fill networks are likely to remain the largest channel throughout the period. Coverage trends remain the main downside risk to this forecast.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.